Are transmembrane 6 superfamily member 2 gene polymorphisms associated with steatohepatitis after pancreaticoduodenectomy?

• Published in: JGH open Vol. 8; no. 6; pp. e13113 - n/a
• Main Authors: Mori, Tomotaka, Ozawa, Eisuke, Sasaki, Ryu, Shimakura, Akane, Takahashi, Kosuke, Kido, Yoko, Kanda, Yasuko, Matsuo, Satoshi, Tajima, Kazuaki, Beppu, Asami, Nakao, Yasuhiko, Fukushima, Masanori, Haraguchi, Masafumi, Miuma, Satoshi, Miyaaki, Hisamitsu, Adachi, Tomohiko, Eguchi, Susumu, Okano, Shinji, Nakao, Kazuhiko
• Format: Journal Article
• Language: English
• Published: Melbourne Wiley Publishing Asia Pty Ltd 01.06.2024; John Wiley & Sons, Inc; Wiley
• Subjects: Body mass index; Chemotherapy; Consent; Diabetes; hepatic fibrosis indexes; Hospitals; Liver cirrhosis; Liver diseases; Malnutrition; Pancreatic cancer; Pancreaticoduodenectomy; Patients; PNPLA3; Polymorphism; Proteins; Spleen; steatohepatitis; TM6SF2; Tomography
• ISSN: 2397-9070; 2397-9070
• DOI: 10.1002/jgh3.13113

Aim After pancreaticoduodenectomy, 20–40% of patients develop steatotic liver disease (SLD), and steatohepatitis can be a problem. Although patatin‐like phospholipase domain‐containing 3 protein (PNPLA3) and transmembrane 6 superfamily member 2 (TM6SF2) polymorphisms are involved in SLD and steatohepatitis development, whether this is the case after pancreaticoduodenectomy is unclear. Methods and Results Forty‐three patients with pancreatic cancer who underwent pancreaticoduodenectomy at our hospital between April 1, 2018, and March 31, 2021, were included. We extracted DNA from noncancerous areas of residual specimens after pancreaticoduodenectomy and determined PNPLA3 and TM6SF2 gene polymorphisms using real‐time polymerase chain reaction. SLD was defined as a liver with an attenuation value of ≤40 HU or a liver‐to‐spleen ratio of ≤0.9 on computed tomography. We defined high hepatic fibrosis indexes (HFI) instead of steatohepatitis as a Fibrosis‐4 index of ≥2.67 or nonalcoholic fatty liver disease fibrosis score of ≥0.675 in patients with SLD. The cumulative incidence of SLD (P = 0.299) and high HFI (P = 0.987) after pancreaticoduodenectomy were not significantly different between the PNPLA3 homozygous and minor allele groups. The incidences of high HFI at 1 year after pancreaticoduodenectomy were 16.8% and 27.0% in the TM6SF2 major homozygous and minor allele groups, respectively, with a significant difference in the cumulative incidence (P = 0.046). Conclusion The TM6SF2 minor allele may contribute to steatohepatitis development after pancreaticoduodenectomy. Forty‐three patients with pancreatic cancer who underwent pancreaticoduodenectomy (PD) were included. we diagnosed steatotic liver disease (SLD) using CT and high hepatic fibrosis indexes (HFI) instead of steatohepatitis in SLD cases. The incidences of high HFI at 1 year after PD were 16.8 % and 27.0 % in the TM6SF2 major homozygous and minor allele groups, respectively, with a significant difference in the cumulative incidence (p = 0.046). The TM6SF2 minor allele may contribute to steatohepatitis development after pancreaticoduodenectomy.